Loading stock data…
ANNX
$5.75-0.12 (-2.04%)
Market ClosedLast close May 1
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Annexon, Inc. in the Healthcare sector is trading at $5.75. The stock is currently 20% below its 52-week high of $7.18, remaining 35.3% above its 200-day moving average. Technical signals show neutral RSI of 49 and bearish MACD signal, explaining why ANNX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 49) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.75
Potential Upside
5%
Whystock Fair Value$6.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinica...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.66%
Volume
Today's trading volume
1.20M
Recent News
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
Annexon Inc. (NASDAQ:ANNX) is one of the small cap stocks with the highest upside potential. On March 30, the company reported its 2025 year-end financial results, highlighting a period of significant clinical and regulatory progress for its neuroinflammatory disease platform. The company ended the year with a strong balance sheet featuring $238.3 million in cash […]
Annexon Biosciences (ANNX) Buy Rating Retained
Annexon Biosciences (NASDAQ:ANNX) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The company’s shares have skyrocketed by 289.29% over the past year and by 39.45% year-to-date. On April 16, Needham analyst Joseph Stringer assigned a Buy rating on Annexon Biosciences and set a price target of $11.00. In March, Annexon […]
Annexon CEO Touts “Win Year” 2026 at Needham, Eyes GA Phase III Data and GBS FDA Filing
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined a series of anticipated clinical and regulatory milestones during the 25th Annual Needham Healthcare Conference, describing 2026 as a “win year” after more than a decade of work developing therapies that target the classical complement pathw
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
The mean of analysts' price targets for Annexon (ANNX) points to a 165.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Annexon ( NASDAQ:ANNX...